RT Journal Article SR Electronic T1 Efficacy of basis therapy and level of immunoregulatory T-cells (T-regs) in COPD JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P2304 VO 40 IS Suppl 56 A1 Natalya Kirillova A1 Elena Kremer A1 Ivan Deev A1 Ludmila Ogorodova A1 Georgiy Chernogoruk A1 Evgeny Kulikov A1 Sergey Fedosenko YR 2012 UL http://erj.ersjournals.com/content/40/Suppl_56/P2304.abstract AB Background. COPD is heterogeneous disease with variable clinical and radiographic signs, different response to therapy and rate of decline in lung function and survival of patients. The levels of T-regs could influence on the efficiency of the basis therapy of COPD.Aim and objectives. Compare the data of COPD clinical course dynamics during basic therapy and levels of inducible (CD4+FOXP3+) T-regs.Methods. Were included 60 patients with COPD stages II-IV, mean age was 57,8±1,09 years, m/f=50/10, mean duration of disease was 10,6±1,05 years. The observation period was 24 weeks after administration of appropriate basis therapy (GOLD reccomendations). At visits were performed spirometry, index BODE, SGRQ. Peripheral blood mononuclear cells were isolated from heparinized blood on Ficoll density gradient (1,077 g/ml). The circulating percentage of CD4+FoxP3+ T-regs in peripheral blood was estimated by the flow cytometry analysis (FACSCalibur Becton Dickinson, USA) using appropriate monoclonal antibodies.Results. Persons with the levels of CD4+FoxP3+ T-regs cells less than 7% in peripheral blood, were characterized by significant reductions in SGRQ-scores from 53,29±0,36 points at visit 1 to 48,24±4,13 points at visit 2 (p<0,05); stable increase in FEV1 from 37,7±3,08% (visit 1) to 46,63±3,39% (visit 2) (p<0,05); decreased BODE index from 4,10±0,37 points (visit 1) to 3,46±0,43 points (visit 2) (p<0,05). COPD patients with the the level of CD4+FoxP3+ more then 7% didn't have the positive dynamics of clinical and functional parameters as a result of a 24-week treatment (p>0,05).Conclusions. High level of CD4+FoxP3+ T-regs (>7%) is associated with impaired response to basis therapy COPD.